Raymond James Raises PT on Tenet Healthcare Corporation (THC) to $200 From $185

Tenet Healthcare Corporation (NYSE:THC) is one of the best strong buy healthcare stocks to buy now. On July 23, Raymond James raised the firm’s price target on Tenet Healthcare Corporation (NYSE:THC) to $200 from $185, keeping an Outperform rating on the shares.

The rating update came after Tenet Healthcare Corporation (NYSE:THC) announced its Q2 results on July 22. The analyst told investors in a research note that the company’s Q2 results surpassed expectations, suggesting a strong quarter.

However, James also stated that the stock move after the results was “a bit surprising” and “overdone.”

Tenet Healthcare Corporation (NYSE:THC) reported a 74% increase in adjusted diluted earnings per share to $4.02 in Q2 2025, compared to $2.31 in the same quarter last year. Consolidated adjusted EBITDA for the quarter also rose 18.6% to $1.121 billion compared to Q2 2024.

Management expects the FY 2025 adjusted EBITDA outlook to be in the range of $4.40 billion to $4.54 billion, reflecting a $395 million increase at the midpoint.

Tenet Healthcare Corporation (NYSE:THC) provides healthcare services. The company’s operations are divided into the Hospital Operations and Ambulatory Care segments.

While we acknowledge the potential of THC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.